Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to ...

(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar. The company ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

When shares of Zimmer Biomet (NYSE:ZBH) moved down to the $105 mark in September, I believed that real value was showing up. Shares sold off despite the projection of mid-single digit sales growth ...

Zimmer Biomet provided 2025 guidance of constant currency revenue growth between 3%-5% and adjusted EPS in the range of $8.15 to $8.35. These projections exclude the impact of the Paragon 28 ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Zimmer Biomet beat analysts’ revenue expectations by ...

On Thursday, Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. The orthopedic giant reported ...